

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number  
**WO 03/064630 A2**

(51) International Patent Classification<sup>7</sup>: **C12N 5/00**

(21) International Application Number: **PCT/EP03/03631**

(22) International Filing Date: **8 April 2003 (08.04.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
0208041.4 **8 April 2002 (08.04.2002)** **GB**  
60/411,751 **19 September 2002 (19.09.2002)** **US**

(71) Applicant (for all designated States except US): **LONZA BIOLOGICS PLC.** [GB/GB]; 228 Bath Road, Slough, Berkshire SL1 4DY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAINWARING, David** [GB/GB]; 38 Braemar Gardens, Slough SL1 9DD (GB). **WAYTE, Jeremy** [GB/GB]; 34B High Street, Marlow, Buckinghamshire SL7 1AW (GB).

(74) Common Representative: **LONZA BIOLOGICS PLC.**; Legal Department, 228 Bath Road, Slough, Berkshire SL1 4DY (GB).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

**Published:**

— upon request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a)  
— without international search report and to be republished upon receipt of that report  
— without classification; title and abstract not checked by the International Searching Authority

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CELL CULTURE MEDIUM**

(57) Abstract: A method for culturing cells in the presence of an alcanoic acid for enhancing protein production.

## Cell culture medium

The present invention relates generally to the field of animal cell culture. It devises a method of culturing animal cell for production of therapeutic or other useful proteins and a  
5 respective cell culture medium.

Sodium butyrate or other salts of butyric acid are well-known to enhance yield of protein produced in animal cell culture as is described e.g. in EP-239 292 A. The effect can be observed for naturally secreted proteins, e.g. antibodies from hybridomas, or recombinant  
10 cell lines. Butyrate is added to cell culture medium in a concentration of preferably up to 5 mM. The effect of butyric acid is rather specific as is confirmed by a wealth of scientific literature on addition of butyric acid to culture medium; propionate or pentanoate are considerably less effective at concentrations at about 1 mM.

However, there are limitations and backdraws to the use of butyrate as a cell culture  
15 supplement. Addition of butyrate in the 0.1-10 mM range needs to be carefully balanced in order to avoid overdosing and the ensuing toxic and cytostatic effects. The negative effect on growth rate can be drastic even upon minor increases in concentration. For each cell line and recombinant clone, the optimal amount of butyrate has to be carefully chosen and controlled during large scale bioreactor cultivation. E.g., according to EP-239 292 A, for  
20 hybridoma cells a concentration range of from 0.1 mM to 1 mM is recommended, whereas other cell lines may well tolerate butyrate at concentrations beyond 1 mM. It is well-known that hybridoma cells are much more sensitive for adverse effects of e.g. insufficient oxygen or nutrient supply or toxic influences of chemical compounds than are other cell types, and that they will easily and irreversibly start programmed cell death once having received  
25 such negative stimulus. In as much, butyrate has proven to be a somewhat Janus-faced means for increasing productivity in cell culture.

Kim et al. (Biotechnology and Bioengineering 71, 2001, 184-193, Overexpression of bcl-2 inhibits sodium butyrate-induced apoptosis in CHO cells resulting in enhanced humanized  
30 antibody production) countered the cytotoxic effect of sodium butyrate at 5mM by means of bcl-2 recombinant cell lines which measure resulted in enhanced protein production. However, this method requires extensive cell line engineering for creating recombinants producing both rekombinant bcl-2 and a product protein. A more simple method to counter

the negative effects of butyrate medium supplements would be advantageous.

5 US 5378 612 describes a synergistic, protein yield enhancing effect of adding lithium salts (10mM) or lipopolysaccharide (LPS, 1µg/ml) to a culture medium for CHO cell culture already comprising sodium butyrate at 1 mM. For two different lithium salts, the yield effect was in the order of 1.3 times, whereas LPS showed an enhancing effect of about 4 times in comparison to the butyrate control. Interestingly, sodium acetate at 10mM proved  
10 to be of literally no benefit over the control in this test system.

Kooistra et al. (Biochem. J. 1987, Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells, 247:605-612) tested in serum-containing, endothelial cell culture various compounds on their potentially expression-enhancing effect  
15 on tPA production, amongst them several alcanoic acids including acetate at 5 mM. Only propionate, valerate and, with outstanding effect, butyrate were found to have such effect. Acetate did not differ significantly from the control.

It is an object of the present invention to avoid the disadvantages of the prior art and to  
20 devise another method for enhancing the yield of product protein in animal cell culture.

This object is achieved according to the present invention by a method for culturing animal cells wherein a cell culture medium is supplemented with acetate; another object of the present invention are the corresponding cell culture media comprising acetate according to  
25 the independent claims 1,6,10,11 and 12.

Possible embodiments of the invention are shown in the figures and tables:

Fig. 1 shows the effect of potassium and sodium acetate on NS0 productivity in fed-batch shake flask culture.

30

Fig. 2 shows NS0 growth profiles for fed-batch bioreactor fermentations containing no or 10 mM sodium acetate.

Fig. 3 shows the effect of 10 mM sodium acetate on NS0 productivity in the fermentation run according to Fig. 2.

Fig. 4 compares the effect on NS0 of inclusion of sodium acetate in inoculum cultures (in inoc) and the timing of further acetate addition (at inoculation or during mid-exponential phase, i.e. at feed). All values are expressed as percent difference compared to control.

Fig. 5, 6 show the growth and antibody productivity of recombinant NS0 cells with 7.5 mM acetate in a custom-made high-density growth medium.

Fig. 7, 8 show dose-response curves for supplementation of NS0 cell culture with sodium acetate.

Fig. 9-11 show comparative data for supplementation of NS0 cell culture medium with sodium n-butyrate.

Fig. 12-14 show dose-response curves for supplementation of a VPM 8 hybridoma cell culture with sodium acetate.

Fig. 15-17 show comparative data for supplementation of a VPM 8 hybridoma cell culture with sodium n-butyrate.

According to the present invention, a method of producing a product protein is devised wherein the product protein is expressed from a mammalian cell in cell culture and is produced at least during a certain span of time during cell culture. That is, the product protein might either be constitutively expressed by the cell or expression might be induced at some point of time by providing a certain stimulus to the cell. Preferably, it is constitutively expressed. The method according to the present invention further comprises the steps of

- a) preparing a cell culture medium for mammalian cells,
- b) and further adding acetic acid or an acetate salt or a biologically activated acetyl

ester to a final concentration of from 1 to 20 mM, preferably of from 3 to 15 mM, more preferably of from 5 to 12 mM, most preferably of from 6 to 9.5 mM, said addition being carried out either directly to the medium prior to starting cell culture or feeding it to the medium during cell culture,

- 5 c) further culturing the mammalian cell in said medium with concomittant expression of product protein,
- d) and finally harvesting said protein from the cell culture.

10 In a further preferred embodiment, the concentration of the acetic acid or the salt or the biologically acitivated ester is from 6 to 20 mM, more preferably of from 6 to 12 mM, most preferably of from 6 to 9.5 mM as may be inferred from combining the above said preferred concentration ranges.

A product gene according to the present invention is the product protein that is sought to be  
15 expressed and harvested in high amount. It may be any protein of interest, e.g. therapeutic proteins such as interleukins or enzymes or multimeric proteins or subunits of multimeric proteins such as antibodies or fragments thereof. The recombinant product gene may include a signal sequence coding sequence portion allowing secretion of the once expressed polypeptide from the host producer cell. The product protein may be a  
20 recombinant protein expressed from a transgenic promoter or it is a naturally active gene locus, such as e.g. an immunoglobuline gene locus in hybridoma cells created by conventional cell fusion techniques. Harvesting and downstream processing techniques for purification of the protein from the culture broth are well-known in the art and a routine task. Initially, techniques such as centrifugation, ultrafiltration and/or ion exchange  
25 chromatography are often applied since they allow for high-volume throughput.

An acetate salt according to the present invention can be any salt such as alkali metal or alkaline earth metal or any other metal acetate salt may be employed. Since media are usually buffered, addition of acetic acid or acetic anhydride is also conceivable, though a  
30 salt will be preferred. Likewise, easily dissociable complex salts of actetate or esters of acetic acid that are liberating acetate in situ in the culture medium during culture, either due to a high rate of hydrolysis or due to activity of cellular exoenzymes, can be employed. Such can be termed, in particular if applying to exoenzyme activity, 'biologically

activatable' esters. Alkali and alkaline earth metal salts of acetate are preferred embodiments of the present invention. More preferably, the salt is an alkali metal salt with the proviso that the alkali metal is not lithium, most preferably, it is sodium acetate. Sodium acetate is particularly preferred in combination with a concentration range of 6 to 9.5 mM in a cell growth medium, as being opposed to a maintenance medium, and upon treatment of the cells with sodium acetate at the onset or prior to the onset of cell culture or both, as set forth below.

Preferably, the cell culture medium of the present invention is devoid of butyrate. Butyrate easily decreases growth rate and induces apoptosis; its concentration needs to be carefully balanced. However, according to the present invention, it can be easily substituted by acetate showing almost no or a very moderate effect on growth rate. Acetate is not known to induce apoptosis.

According to the present invention, acetate or its equivalents are added either directly to the fresh medium prior to starting cell culture or feeding it to the medium during cell culture, preferably during exponential phase growth in a growth medium. In case of feed addition, it should be taken into account that the effect of acetate takes place with some delay, i.e. a lag phase is observable with regard to the product protein yield enhancing effect. In general, addition of acetate via feed only is less effective. Addition of acetate directly to the cell culture medium, preferably a cell growth culture medium, prior to cell culturing and in the amounts stated above is strongly preferred according to the present invention, optionally in conjunction with further feed of acetate depending on the concentration. Most preferably, acetate is added only directly to the culture medium prior to culture onset, in the amounts stated above and in particular at 6 to 9 mM and in the form of sodium acetate, and is not replenished during cell cultivation via feed, preferably it is not replenished during culture growth in a suitable medium such as a high cell density growth medium.

'Addition to the medium prior to starting cell culture' according to the present invention means exposing cells at about the time of inoculation which includes the initial lag-phase before the onset of detectable growth or exposing them even prior to inoculation of the culture medium to acetate or its equivalents in the above stated amounts. Again, 'prior to inoculation' means that the inoculum pre-culture itself is grown in a medium comprising

the acetate medium supplement in the above stated amounts. It is also possible to combine both aspects. In one particularly preferred embodiment, only the inoculum culture is treated with acetate in the amounts stated above whereas the cell culture growth medium used for large-scale production culture is devoid of acetate salts in the >1mM range.

5

Suitable cells or cell lines can be any mammalian cell line. Suitable cell lines can be e.g. SV-40 immortalized monkey kidney cells (COS-7) cells, canine kidney cells (MDCK), african green monkey kidney cells (VERO-76), baby hamster kidney (BHK) cells such as ATCC CCL10, human liver cells (Hep G2), lymphocytic cells (Jurkat T-cell line),

10 hybridoma cells (e.g. SP2/0-Ag14, Shulman et al. 1977) or ,myeloma' cells (such as e.g. NSO cells). It is to be understood that not all those cells will equally well respond to the addition of acetate to the cell culture medium. In addition, for a given cell type or cell line, the effect of acetate may not be linear or constant within the acetate concentration ranges specified above. Depending on cell line, it may display an individual concentration  
15 optimum at which the yield enhancing effect of acetate is maximal and is decreased when shifting acetate concentration to either lower or higher amounts; the optimum concentration may vary considerably in between cell types and may need to be established by simple dose response experimentation.

20 Suitable media and culture methods for mammalian cell lines are well-known in the art, as described in US 5633162 for instance. Examples of standard cell culture media for laboratory flask or low density cell culture and being adapted to the needs of particular cell types are for instance: Roswell Park Memorial Institute (RPMI) 1640 medium (Morre, G., The Journal of the American Medical Association, 199, p.519 f. 1967), L-15 medium  
25 (Leibovitz, A. et al., Amer. J. of Hygiene, 78, 1p.173 ff, 1963), Dulbecco's modified Eagle's medium (DMEM), Eagle's minimal essential medium (MEM), Ham's F12 medium (Ham, R. et al., Proc. Natl. Acad. Sc.53, p288 ff. 1965) or Iscoves' modified DMEM lacking albumin, transferrin and lecithin (Iscoves et al., J. Exp. med. 1, p. 923 ff., 1978). It is known that such culture media can be supplemented with fetal bovine serume  
30 (FBS, also called FCS), the latter providing a natural source of a plethora of hormones and growth factors. Cell culture of vertebrate and mammalian cells, respectively, has become a routine matter and is covered in detail e.g. in R. Ian Fresney, Culture of Animal cells, a manual, 4<sup>th</sup> edition, Wiley-Liss/N.Y., 2000.

Preferably, the cell culture medium according to the present invention is a medium allowing for and supporting growth of the animal cells thus cultured. Growth is understood as an increase in viable cell density during at least a certain period of the cell culture.

5 According to the present invention, such definition of 'growth medium' is to be understood as being opposed to the term 'maintenance medium' in its usual meaning in the art. A maintenance medium is a cell culture medium which supports cell viability but which does not encourage cell growth. Often, such maintenance media do not contain essential growth factors such as transferrin, insulin, albumin and the like.

10

Said embodiment of the medium being a mammalian cell culture medium comprising acetate or its equivalents in the afore mentioned amounts applies in particular to culturing or to a medium suited for the culture of lymphoid cells such as e.g. hybridoma and myeloma cells. The term hybridoma includes not only antibody secreting cells obtained by  
15 cell fusion, including so-called quadromas and the like, but as well B-lymphocytic, antibody secreting cells obtained by immortalization with an immortalizing agent such as a recombinant gene product having cell cycle activity or a virus, e.g. Eppstein-Barr-Virus, or any chemical, immortalizing agent. In the present context, 'hybridoma' extends as well to non-secreting hybridomas such as e.g. SP2/0-Ag14, Shulman et al. 1977. Therefore, a  
20 product protein sought to be harvested from a hybridoma in the present context does not relate necessarily to a homologous gene product such as an antibody from a parent cell but may as well be a recombinant product protein.

Preferably the cells are ,myeloid', most preferably they are a myeloma NS0 cell line (such  
25 as e.g. cell line ECACC No. 85110503 and derivatives thereof, freely available from the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology & Research, Salisbury, Wiltshire SP4 0JG, United Kingdom). ,Myeloid' cells are tumor cell lines of which NS0 is one example. NS0 cells are actually plasmacytomas and are in consequence of B-lymphocytic lymphoid cell lineage as are hybridomas, though being  
30 adressed in the art routinely and quite incorrectly as being ,myeloid' cells (Barnes et al., Cytotechnology 32:109-123, 2000). Corresponding cell types are likewise particularly preferred embodiments in consequence. ,Myeloma' NS0 cells have been found to give potentially rise to extremely high product yields, in particular if used for production of



recombinant antibodies. Most standard NS0 cell lines are cholesterol-dependent, usually making cholesterol an obligate component of the culture medium. According to the present invention, lymphoid cells do comprise hybridoma cells generated by a number of techniques from antibody-secreting cells such as cell fusion with suitable tumor cell lines, including fusion with non-secreting hybridoma cell lines which gives rise to so-called triomas, or immortalisation with a transforming agent or virus as well as any other lymphoid cell line. In another preferred embodiment, however, a mammalian cell or cell line according to the present invention, is not a hybridoma cell line, meaning it is a non-hybridoma cell line, and more preferably it is a non-hybridoma, recombinant cell line, most preferably a recombinant 'myeloma' cell line as defined above.

In a further preferred embodiment, the cell line is a NS0 cell line which is capable to express recombinant glutamine synthetase (GS). NS0 cells are specifically of advantage if used with the Glutamine synthetase (GS) expression system (Bebbington et al., 1992, High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker, *Bio/Technology* 10:169-175; Cockett et al., 1990, High level expression of tissue inhibitor of metalloproteinases in Chinese Hamster Ovary (CHO) cells using Glutamine synthetase gene amplification, *Bio/Technology* 8: 662-667). Preferably, the product protein gene sequence and the GS gene sequence are carried on a single GS plasmid vector for generating said transfected NS0 cell line, said genes either being expressed from different or same promoters employing e.g. internal ribosome entry sites. - The GS-system is one of only two systems that are of particular importance for the production of therapeutic proteins. In comparison to the dihydrofolate reductase (DHFR) system, the GS system, and in particular the GS system used in combination with NS0 myeloma cells, offers a large time advantage during development because highly productive cell lines can often be created from the initial transfection thus avoiding the need for multiple rounds of selection in the presence of increasing concentrations of selective agent in order to achieve gene amplification (Brown et al., 1992, Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system, *Cytotechnology* 9:231-236). NS0 cells are phenotypically deficient in Glutamine-synthetase. Therefore the NS0 cell line which was derived from a mouse tumour cell line (Galfre, G. and Milstein, C., *Methods in Enzymol.* 73, 3-75, 1981) is frequently the cell line of choice used in combination with the GS

system at an industrial scale.

Preferably, the cell culture medium according to the present invention is devoid of fetal calf serum (FCS or FBS), which then is being termed 'serum-free'. Cells in serum-free medium generally require insulin and transferrin in a serum-free medium for optimal growth. Transferrin may at least partially be substituted by non-peptide chelating agents or siderophores such as tropolone as described in WO 94/02592 or increased levels of a source of anorganic iron favorably in conjunction with antioxidants such as vitamin C. Most cell lines require one or more of synthetic growth factors (comprising recombinant polypeptides), including e.g. epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin like growth factors I and II (IGFI, IGFII), etc.. Other classes of factors which may be necessary include: prostaglandins, transport and binding proteins (e.g. ceruloplasmin, high and low density lipoproteins, bovine serum albumin (BSA)), hormones, including steroid-hormones, and fatty acids. Polypeptide factor testing is best done in a stepwise fashion testing new polypeptide factors in the presence of those found to be growth stimulatory. Those growth factors are synthetic or recombinant. There are several methodological approaches well-known in animal cell culture, an exemplary one being described in the following. The initial step is to obtain conditions where the cells will survive and/or will grow slowly for 3-6 days after transfer from serum-supplemented culture medium. In most cell types, this is at least in part a function of inoculum density. Once the optimal hormone/growth factor/polypeptide supplement is found, the inoculum density required for survival will decrease.

In a more preferred embodiment, the cell culture medium according to the present invention is protein-free, more preferably it is a protein-free growth medium, that is it is free both of fetal serum and individual protein growth factors supplements or other protein such as recombinant transferrin or serum albumin for lipid binding and transport.

Most preferably, it is a protein free medium as defined above but to which has been added recombinant or purified albumin or a sequence variant or fragment thereof. It should be noted, however, that even for NS0 cell lines which usually require cholesterol as a medium supplement, obtention of cholesterol-independent subspecies has been reported which can be continuously cultured and grown for protein production (Lonza Biologics, UK). Protein-free culture media according to the present invention are particularly preferred in

conjunction with the use of myeloma cell lines such as NS0.

A further preferred, possible embodiment of the method and the below specified cell culture medium of the present invention is high-density fermentation or high-density growth fermentation of the animal cells, e.g. in an industrial fed-batch bioreactor such as an airlift or perfusion bioreactor up to or beyond a viable cell density of up to or beyond  $10^5$  cells/ml, preferably  $10^6$  cells/ml. Consequently, a high-density growth culture medium has to be employed. Such high-density growth media can usually be supplemented with nutrients such as all amino acids, energy sources such as glucose in the range given above, inorganic salts, vitamins, trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), buffers, the four nucleosides or their corresponding nucleotides, antioxidants such as Glutathione (reduced), Vitamine C and other components such as important membrane lipids, e.g. cholesterol or phosphatidylcholine or lipid precursors, e.g. choline or inositol. A high-density medium will be enriched in most or all of these compounds, and will, except for the inorganic salts based on which the osmolarity of the essentially isotonic medium is regulated, comprise them in higher amounts (fortified) than the afore mentioned standard media as can be incurred from EP-435 911 A or GB-2251249 in comparison with RPMI 1640. GB-2251249 gives examples of suitable high-density growth media. In accordance with the present invention, such high density cell culture medium comprises acetate in the amounts stated above, preferably in the absence of a butyrate. Further preferred, a high-density culture medium according to the present invention is balancedly fortified in that a majority of amino acids except for Tryptophane are in excess of 75 mg/l in the culture medium. More preferably, in conjunction with the general amino acid requirement, the joint amounts of Glutamine and Asparagine are in total in excess of 1 g/l, most preferably in excess of 2 g/l of high-density culture medium. It goes without saying that the latter more preferred embodiment is less suitable in case of a recombinant cell line transfected with a Glutamine synthetase (GS) vector, in particular after rounds of amplification of the GS gene sequence have taken place. In those cells, an excess of e.g. glutamine jointly from exogenous and endogenous source would lead to production of ammonia, which is to be avoided.

In the context of the present invention, high-density cell culture is defined as a population of animal cells having temporarily a density of viable cells of at least or in excess of  $10^5$

cells/ml, preferably of at least or in excess of  $10^6$  cells/ml, and which population has been continuously grown from a single cell or inoculum of lower viable cell density in a cell culture medium in a constant or increasing culture volume.

5 In a further preferred embodiment, the cell culture according to the present invention is a fed-batch culture wherein one or several other amino acids, preferably comprising at least Glutamin, is fed to the cell culture as described in GB-2251249 for maintaining their concentration in the medium and apart from controlling Glucose concentration by separate feed. More preferably, the feed of Glutamin and optionally one or several other amino  
10 acids, ideally comprising Glutamine is combined with feeding one or more energy sources such as glucose to the cell culture as described in EP-229 809-A. Glutamine may at least be partly substituted by Asparagine (for substitution of glutamine by asparagine, see Kurano, N. et al., 1990, J. Biotechnology 15, 113-128). Feed is usually initiated at 25-60 hours after start of the culture; for instance, it is useful to start feed when cells have  
15 reached a density of about  $10^6$  cells/ml. The amino acids that can be present in the feed are usually dosed in the range of from 10 to 300 mg total addition per amino acid per litre of culture volume; in particular glycine, lysine, arginine, valine, isoleucine and leucine are usually fed at higher amounts of at least 150 to 200 mg per L of culture volume as compared to the other amino acids. Except for GS cell lines, it can be of benefit to adjust  
20 the total feed of glutamine and/or asparagine to the range of from 0.5 to 3 g per L of culture volume, preferably to the range of from 1 to 2 g per L of culture volume. The feed can be added as shot-addition or as continuously pumped feed, preferably the feed is almost continuously pumped into the bioreactor. It goes without saying that the pH is carefully controlled during fed-batch cultivation in a bioreactor at an approximately physiological  
25 pH optimal for a given cell line by addition of base or buffer. When glucose is used as an energy source the feed of glucose feed is adjusted usually to keep glucose concentration of the medium of from 1 to 10 grams, preferably of from 3 to 6 grams per litre of the culture. Apart from inclusion of amino acids, the feed preferably comprises a low amount of choline in the range of 5 to 20 mg per litre of culture.

30

A corresponding cell culture medium comprising an acetate supplement suited e.g. for NS0 cell culture, a cell culture made up of such cell culture medium and lymphoid and/or NS0 cells and a medium concentrate for preparing such medium are further objects of the

present invention. The above description applies likewise to these embodiments of the present invention.

## Experiments

Where not specified, antibody productivity or titer was determined by protein A-HPLC.

### Experiment 1

5 The GS-NS0 cell line 6A1(100)3, 6A1 for short, secreting recombinant mouse/human chimeric IgG cB72.3 (Bebbington, 1992, supra) was used in all experimental settings under this section. Cell culture was either carried out in shake flask culture or in a fed-batch mode in a 10 l standard airlift bioreactor, essentially as described (Bebbington, 1992). Feeds essentially comprised amino acids and carbohydrate as described above for  
10 high-density media and fermentation, respectively. Feed volume was at 4% of post-inoculation volume. Feed was initiated at a rate of 0.2 ml /Lh when viable cell density exceeded  $14 \times 10^5$  cells/ml. Temperature was controlled at 36.5 degree centigrade; for airlift, air saturation was at 15%. pH was controlled at pH 7.00. Culture was inoculated at  $2 \times 10^5$  viable cells/ml. Medium is serum- and essentially protein-free growth medium ProCH04-  
15 CDM (BioWhittaker) supplemented with 50 mM methionine sulfoximine (MSX). Cells were pre-adapted to medium. Increases in protein yield of up to 98% (from 470 mg/L of the control as compared to 768 mg/L for a strain grown with 10 mM acetate) were observed. Acetate was found not to suppress growth. It slightly decreased growth rate but did not lower maximum viable cell densities. Positively, it did prolong stationary phase  
20 upon fermentation.

Cumulative cell time ( $10^6$  cell /h ml) was calculated by integration of the cell growth curve, essentially as described by Renard et al. (1988, Biotechnology Letters 10, 9  
1-96).

25

Fig. 1 shows the effect of potassium and sodium acetate on productivity in fed-batch shake flask culture. Either sodium acetate or potassium acetate were added to shake flask culture during mid-exponential growth phase to the final concentrations stated in the respective sections of the table of Fig. 1. Cultures were counted daily by Trypan blue method and  
30 samples were taken for product analysis by means of protein A fractionation and HPLC analysis. Sodium acetate at 10 mM performed even better than potassium acetate at either 10 mM or 15 mM. The CCT was similar in all treatments (including control). Consequently, single cell productivity ( $q_p$ ) was found to be increased.

Fig. 2 shows growth profiles for fed-batch bioreactor fermentations containing no or 10 mM sodium acetate. Duplicate cultures both for control and 10 mM sodium acetate supplemented culture were tested for viable cell concentration (determined by Trypan blue exclusion standard counting test). Feed was started at day 4. The acetate was not fed during growth phase as in Fig. 1 but was included in cell culture production medium right away to which the inoculum cells were added. As can be seen, the yield enhancing effect of acetate proved to be highly reproducible (Fig. 3) as was growth behavior. No significant growth suppression could be observed in terms of maximum cell density achievable. Growth rate was not substantially decreased though a certain effect of acetate addition was reproducibly found. The CCT remained essentially similar for all cultures. Notably, acetate improved duration or stability of stationary growth phase; decline of viable cell density after viable cell density peaked was much slower in the presence of acetate. Antibody production is known to be much higher in stationary phase than in exponential growth phase.

In an additional set of experiments, the feed was further supplemented with LiCl both for the control and the culture treated with acetate as said in the preceding paragraph, accumulating to a final concentration of approx. 1-10 mM (data not shown). The addition of a Li-salt did not prove to modify the effect of acetate addition in any way. Certainly, no synergistic enhancement of the effect of acetate addition could be seen as has been reported for n-butyrate supplementation of cultures.

Fig. 4 compares the effect of inclusion of sodium acetate in inoculum cultures (in inoc) or at the time of inoculation to the production medium (at inoc) or in the feed given during mid-exponential phase (at feed) or combinations thereof in fed-batch shake flask culture. All values are expressed as percent difference compared to control. A clear dose dependency was observable as regards the amount of acetate added. Addition of acetate to the inoculum culture or at the time of inoculation, meaning the use of an acetate supplemented culture medium for production culture, was found to be the most effective mode in view of increased yield and maximized single cell productivity.

## Experiment 2

Exp. 2 was conducted essentially as described above for exp. 1/Fig.2, except that now 7.5 mM sodium acetate and a proprietary high-density culture medium was used, similar to the lipid supplemented high-density media described in EP-435 911 A but distinct in employing less ethanolamine and no thioglycerole and keeping Tryptophan concentration constant at 19 mM by sensor-controlled automatic feeding. With such medium, 7.5 mM acetate was found to be optimal for that cell line with regard to antibody yield and process robustness. Fig. 5 shows the CCT diagram for 7.5 mM acetate, demonstrating again that the application of acetate allows of enhancing antibody yield without decreasing growth rate or viable cell density. In contrast to exp. 1, the same maximum viable cell density could be achieved in the presence of acetate as compared to the control without acetate in the absence of any adverse effect on duration of stationary phase growth. Similarly, product concentration increased steadily over control and over time (Fig. 6). Unlike other productivity enhancing agents, such as sodium butyrate, addition of sodium acetate leads to only small decreases in cell growth parameters (cell growth rate and cumulative cell time). Thus addition of sodium acetate leads to a large increase in the harvest antibody concentration.

### Experiment 3

The experiment was a dose-response study for the addition of different amounts of sodium acetate for NS0 cell line 6A1 in the range of up to 20 mM and was conducted essentially as described in exp.1/Fig.2. Fig. 7 shows CCT dependent on dose of acetate added, Fig. 8 shows single cell specific productivity ( $q_p$ ) dependent on dose of acetate added.

### Comparative example: Experiment 4

Butyrate addition to cell culture media does not increase antibody productivity in NS0-6A1 cells; at doses  $> 1$  mM, it is strongly toxic to the cells and decreases viable cell density very rapidly. In the permissible range, no increase in productivity could be seen at all, not even at the single cell level. The experiment was conducted essentially as described in exp. 1/Fig.2, except that butyrate was added in the amounts shown instead of acetate. Later addition of butyrate at the mid-exponential phase did not enhance productivity, either. Fig. 9-11 show the effect of butyrate addition on CCT, antibody titer at harvest and single cell specific productivity ( $q_p$ ).



### Experiment 5

A dose response study for addition of sodium acetate was carried out for hybridoma cell line VPM 8 (ECACC No. 93113024, European Collection of cell cultures, supra) essentially as described in exp. 3, except that VPM 8 was grown in commercial, protein-free medium CD-Hybridoma (Invitrogen/U.K.) and in that no MSX was added, since not being a GS cell line. VPM 8 is a mouse hybridoma that was generated by conventional means of cell fusion with non-secreting myeloma cells and secretes a murine IgG1 antibody. Fig. 12-14 show the effect of acetate addition on CCT, antibody titer at harvest and single cell specific productivity ( $q_p$ ). Notably, in comparison to butyrate, the hybridoma VPM 8 tolerates acetate surprisingly easily in the mM range, in contrast to butyrate (s. exp. 6) and shows enhanced productivity as compared to non-acetate treated control. The latter could not have been expected based on butyrate treatment of such cells known from the prior art (s. exp. 6).

### Comparative example: Experiment 6

Fig. 15- 17 show the effect of n-butyrate treatment of VPM 8 hybridoma cells on CCT, harvest antibody titer and single cell specific productivity ( $q_p$ ), respectively. The experiment has been carried out essentially as described in exp. 5, except that acetate was substituted with n-butyrate in the amounts stated in the figures. Given the exceptional toxicity of butyrate for this cell line, it is hardly possible to add any butyrate at all without decreasing growth rate and viable cell density. Butyrate supplementation therefore is not effective in increasing antibody titer.

**Claims**

1. Method of producing a product protein, wherein the protein is expressed from a  
5 mammalian cell, preferably from a lymphoid cell, in cell culture at least during a  
certain span of time during cell culture, comprising the steps
  - e) preparing a cell culture medium for culturing mammalian cells, preferably  
preparing a cell culture medium that is devoid of butyrate, and further preferred  
preparing a cell culture medium allowing for growth of the mammalian cells, more  
10 preferably a protein-free cell culture growth medium,
  - f) and further adding acetic acid or an acetate salt or an acetyl ester to a final  
concentration of from 1 to 20 mM, preferably of from 3 to 15 mM, more preferably  
of from 5 to 12 mM, most preferably of from 6 to 9.5 mM, said addition being  
carried out either directly to the medium prior to starting cell culture or feeding it to  
15 the medium during cell culture,
  - g) further culturing, preferably growing, said cell in said medium with concomittant  
expression of product protein,
  - h) and finally harvesting said protein from the cell culture.
- 20 2. Method according to claim 1, characterised in the the addition of acetic acid or a salt  
thereof is carried out directly to the medium prior to or at starting the cell culture.
3. Method according to one of the preceding claims, characterised in that an acetate alkali  
metal or alkaline earth metal salt is added to the medium.
- 25 4. Method according to one of the preceding claims, characterised in that the cells are  
lymphoid cells, preferably NS0 cells.
5. Method according to claim 4, characterised in the cells are NS0 cells that are  
30 recombinant for and can express Glutamine synthetase.
6. Cell culture medium for animal cell culture, characterised in that the medium is suited  
for culturing mammalian cells and comprises acetic acid or an acetate salt or a


biologically activated acetyl ester at a concentration of from 1 to 20 mM, preferably of from 3 to 15 mM, more preferably of from 5 to 12 mM, most preferably at about 6 to 9.5 mM, and preferably is devoid of butyric acid or any of its salts.

- 5 7. Cell culture medium according to claim 3, characterised in that the medium is a high density cell culture medium.
8. Cell culture medium according to claim 6 or 7, characterised in that the medium is a cell culture medium allowing of growth of animal cells, preferably lymphoid cells.
- 10 9. Cell culture medium according to claims 6-8, characterised in that the medium is a serum-free and protein-free cell culture medium, preferably a protein-free medium suitable for NS0 cell culture.
- 15 10. A medium concentrate for preparation of a culture medium as defined in claim 6 which is either a solid or a liquid.
11. Use of a cell culture medium according to claim 6 for lymphoid cell culture.
- 20 12. Cell culture, comprising mammalian cells, preferably lymphoid cells, most preferably NS0 cells, in a medium according to claim 6.

Parameter	Control	Potassium acetate (mM)			Sodium acetate (10 mM)
		5	10	15	
CCT ( $10^6$ cell h mL <sup>-1</sup> )	554	597 (8%)	593 (7%)	572* (3%)	535 (-3%)
Product (mg L <sup>-1</sup> )	365	448 (23%)	480 (32%)	487* (33%)	501 (37%)
q <sub>p</sub> (mg 10 <sup>6</sup> cells <sup>-1</sup> h <sup>-1</sup> )	0.659	0.752 (14%)	0.810 (23%)	0.852 (29%)	0.937 (42%)

- \* A duplicate culture exhibited very poor cell growth. No product concentration was determined.

Δ ± 1






Fig. 1

Fig. 4

Treatment	Maximum viable cell concentration	CCT	Product concentration	qp
No acetate (Control)	0%	0%	0%	0%
5mM in inoculum	-4%	23%	24%	12%
10mM in inoculum	24%	40%	97%	56%
5mM at feed	8%	-13%	-15%	-5%
10mM at feed	1%	-8%	8%	17%
15mM at feed	26%	7%	1%	-3%
5mM in inoc - 10mM at inoc	9%	59%	98%	39%
5mM in inoc - 10mM at feed	12%	47%	73%	28%

Fig. 5




Fig. 6






Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13








Fig. 14



**Fig. 15****Fig. 16**

**Fig. 17**

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03631

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C12N5/02 C07K16/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 239 292 A (CELLTECH LIMITED) 30 September 1987 (1987-09-30) cited in the application the whole document	1-12
A	US 5 378 612 A (NAKASHISMA K. ET AL.) 3 January 1995 (1995-01-03) cited in the application the whole document	1-12
	----- -/-- -----	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

15 October 2003

Date of mailing of the international search report

27/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Moreau, J.



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03631

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KIM N S ET AL: "Overexpression of bcl-2 inhibits sodium butyrate-induced apoptosis in Chinese hamster ovary cells resulting in enhanced humanized antibody production." BIOTECHNOLOGY AND BIOENGINEERING. 2000-2001, vol. 71, no. 3, 2000, pages 184-193, XP002257847 ISSN: 0006-3592 cited in the application the whole document</p> <p>-----</p>	1-12

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03631

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0239292	A	30-09-1987	AT 95231 T	15-10-1993
			AU 7126487 A	09-10-1987
			CA 1341367 C	11-06-2002
			DE 3787551 D1	04-11-1993
			DE 3787551 T2	17-02-1994
			EP 0239292 A1	30-09-1987
			ES 2059367 T3	16-11-1994
			WO 8705626 A1	24-09-1987
			GB 2196636 A , B	05-05-1988
			JP 2525436 B2	21-08-1996
			JP 63503273 T	02-12-1988
			US 2002132299 A1	19-09-2002
			US 5681718 A	28-10-1997
			US 6413746 B1	02-07-2002
			US 6117652 A	12-09-2000
			US 6228618 B1	08-05-2001
<hr/>				
US 5378612	A	03-01-1995	JP 2683946 B2	03-12-1997
			JP 4020294 A	23-01-1992
			JP 2696001 B2	14-01-1998
			JP 4316484 A	06-11-1992
<hr/>				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**